Press Release
Duane Morris Chicago Office Adds Intellectual Property Partner Kevin M. Nelson
CHICAGO, January 29, 2013—Duane Morris is pleased to announce that Kevin M. Nelson has joined the firm's Intellectual Property Practice Group as a partner in its Chicago office. Nelson further strengthens Duane Morris' IP practice, particularly in its growing generic pharmaceuticals and Hatch-Waxman practice. Duane Morris is one of the leading law firms representing generic and biogeneric companies in IP litigation, products liability and regulatory matters, and is committed to maintaining its active and growing practice in this area. Nelson joins Duane Morris from Locke Lord LLP.
Nelson focuses his practice on complex pharmaceutical patent litigation. For the past 12 years, he has represented generic drug companies in patent litigation brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Nelson has had substantial first-chair trial experience and has represented clients before the U.S. Court of Appeals for the Federal Circuit. Nelson has also represented clients before the U.S. Food and Drug Administration (FDA) in regulatory matters and in opposing citizen petitions. In addition, he has experience advising clients regarding biosimilars applications and litigation. Nelson also has experience in copyright and trademark litigation, trademark oppositions, antitrust litigation and client counseling on electronic discovery readiness.
Nelson frequently writes on topics, including the impact of FDA guidances and other patent litigation matters.
He earned his J.D. in 2001 from DePaul University College of Law and graduated with a B.A. in Political Science in 1998 from Indiana University.
About Duane Morris' Generic Pharmaceuticals Practice
Duane Morris lawyers have significant experience with the complexities involved in bringing generic pharmaceuticals to market. Our lawyers' and registered patent agents' experience involves biotechnology processes and products, chemical processes, synthesis and products, medical devices, formulations, experiments and polymorphic products to name a few.
Attorneys at Duane Morris specialize in the representation of worldwide generic pharmaceutical companies in their quest to enter the U.S. market with new products. We have significant experience in representing clients in litigation related to abbreviated new drug applications (ANDAs) filed under the Hatch-Waxman law, as well as generation of non-infringement, invalidity and freedom-to-operate opinions with respect to patents listed in the Orange Book.
About Duane Morris
Duane Morris LLP, a law firm with more than 700 attorneys in offices across the United States and internationally, is asked by a broad array of clients to provide innovative solutions to today's legal and business challenges.
